122 related articles for article (PubMed ID: 25370819)
1. The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells.
Carlisi D; Lauricella M; D'Anneo A; Buttitta G; Emanuele S; di Fiore R; Martinez R; Rolfo C; Vento R; Tesoriere G
J Cell Physiol; 2015 Jun; 230(6):1276-89. PubMed ID: 25370819
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
4. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells.
Chiao MT; Cheng WY; Yang YC; Shen CC; Ko JL
Autophagy; 2013 Oct; 9(10):1509-26. PubMed ID: 23962875
[TBL] [Abstract][Full Text] [Related]
7. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
[TBL] [Abstract][Full Text] [Related]
9. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
10. Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells.
Zhang S; Lin ZN; Yang CF; Shi X; Ong CN; Shen HM
Carcinogenesis; 2004 Nov; 25(11):2191-9. PubMed ID: 15256485
[TBL] [Abstract][Full Text] [Related]
11. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
12. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Librizzi M; Caradonna F; Cruciata I; Dębski J; Sansook S; Dadlez M; Spencer J; Luparello C
Chem Res Toxicol; 2017 Dec; 30(12):2187-2196. PubMed ID: 29129070
[TBL] [Abstract][Full Text] [Related]
13. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Rundall BK; Denlinger CE; Jones DR
Surgery; 2004 Aug; 136(2):416-25. PubMed ID: 15300209
[TBL] [Abstract][Full Text] [Related]
14. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
15. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer.
D'Anneo A; Carlisi D; Lauricella M; Puleio R; Martinez R; Di Bella S; Di Marco P; Emanuele S; Di Fiore R; Guercio A; Vento R; Tesoriere G
Cell Death Dis; 2013 Oct; 4(10):e891. PubMed ID: 24176849
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
Seo SK; Jin HO; Lee HC; Woo SH; Kim ES; Yoo DH; Lee SJ; An S; Rhee CH; Hong SI; Choe TB; Park IC
Mol Pharmacol; 2008 Mar; 73(3):1005-12. PubMed ID: 18156316
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
Cao H; Cheng Y; You L; Qian J; Qian W
Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
